Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31135837.
- Also identified by DOI 10.1001/jama.2019.4492 and PMC identifier 6547115.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.
Medical subject headings
- Antineoplastic Agents
- Health Expenditures
- Medicare Part D
- Prescription Fees